FY25 Result - ASX & Media Release

• Sales revenue increased 4% (3% in constant currency) to $2,356 million
• Statutory net profit increased 9% to $389 million
• Underlying net profit increased 1% to $392 million
• FY26 underlying net profit guidance range is $435-460 million, an 11-17% increase on FY25

In FY25, Cochlear helped over 53,000 people hear with its cochlear or acoustic implants, providing an estimated net social benefit of more than $9 billion. The company reached a major milestone by launching the Cochlear Nucleus Nexa System, the world's first and only smart cochlear implant system with upgradeable firmware. Sales revenue increased 4% (3% in constant currency) to $2,356 million, with strong growth in cochlear and acoustic implants partially offset by a decline in Services revenue. Statutory net profit increased 9% to $389 million, while underlying net profit increased 1% to $392 million. The company's FY26 underlying net profit guidance range is $435-460 million, an 11-17% increase on FY25. Cochlear continued to invest in research and development, with a focus on improving hearing outcomes for recipients through innovations such as drug-eluting electrodes. The company also made progress in its digital transformation and sustainability initiatives, including reducing Scope 1 and 2 emissions by 71% from the FY19 baseline.

FY26 underlying net profit guidance range is $435-460 million, an 11-17% increase on FY25.